{"schema_version":"secwatch.filing_event.v1","accession":"0000886163-23-000004","form_type":"8-K","ticker":"LGND","cik":"0000886163","company_name":"LIGAND PHARMACEUTICALS INC","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.404579+00:00","generated_at":"2026-06-19T06:02:12.648833+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ligand Q4 revenue $50.4M, net loss $14.5M; raises 2023 guidance on royalties and EPS","bullets":["Q4 total revenues $50.4M (down 11% YoY); royalties $22.0M (up 25% YoY); net loss from continuing ops $14.5M ($0.86 per share).","Full year 2022 total revenues $196.2M (down 19% YoY); adjusted net income $82.2M ($4.79 per diluted share) vs $108.0M ($6.27) in 2021.","2023 guidance raised: royalties $74-78M (prev $72-76M), total revenue $120-124M, adjusted diluted EPS $3.30-3.45 (prev $3.10-3.30).","Travere's FILSPARI received FDA accelerated approval for IgA nephropathy; Verona positive Phase 3 for ensifentrine in COPD.","OmniAb spin-out completed Nov 1, 2022; cash and investments $211.9M at year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0000886163-23-000004","json":"https://secwatch.observer/filing/0000886163-23-000004.json","markdown":"https://secwatch.observer/filing/0000886163-23-000004.md","text":"https://secwatch.observer/filing/0000886163-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000004/0000886163-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000004/lgnd-20230222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:02:12.648833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ad262b59782d3266f6ad3f0a6a94e7535ba091e","claim":"LIGAND PHARMACEUTICALS INC reported the fourth quarter of 2022 results: revenue $50.4 million, net income $14.5 million net loss, EPS $0.86 per share. Guidance raised.","evidence_excerpt":"Total revenues for the fourth quarter of 2022 were $50.4 million, compared with $56.4 million for the same period in 2021. Royalties for the fourth quarter of 2022 were $22.0 million, compared with $17.6 million for the same period in 2021, with the increase primarily attributable to the growth in sales of drugs using the Pelican platform. Core Captisol sales were $3.3 million for the fourth quarter of 2022, compared with $7.1 million for the same period in 2021. The difference in sales was due to the timing of customer orders. Captisol sales related to COVID-19 were $23.5 million for the fourth quarter of 2022, compared with $28.3 million for the same period in 2021. Contract revenue was $1.5 million for the fourth quarter of 2022, compared with $3.5 million for the same period in 2021. The difference was due to the timing of partner milestone events. Cost of Captisol was $21.6 million for the fourth quarter of 2022, compared with $12.0 million for the same period in 2021, with the in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000004/0000886163-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter of 2022"},{"label":"Revenue","value":"$50.4 million"},{"label":"Net income","value":"$14.5 million net loss"},{"label":"EPS","value":"$0.86 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b687ff34c3063b2069f9271a1c00684e8c74b8fa","claim":"LIGAND PHARMACEUTICALS INC reported 2022 results: revenue $196.2 million, net income $5.2 million net loss, EPS $0.31 per share. Guidance raised.","evidence_excerpt":"Total revenues for 2022 were $196.2 million, compared with $241.5 million for 2021. Royalties for 2022 were $72.5 million, compared with $48.9 million for 2021, with the increase primarily attributable to the growth in sales of drugs using the Pelican platform. Core Captisol sales were $16.4 million for 2022, compared with $23.4 million for 2021. The difference in sales was due to the timing of customer orders. Captisol sales related to COVID-19 were $88.1 million for 2022, compared with $140.8 million for 2021. The lower sales are due to reduced demand for the pandemic-related treatment. Contract revenue for 2022 was $19.2 million, compared with $28.4 million for 2021, with the change due to the timing of partner milestone events. Cost of Captisol was $52.8 million for 2022, compared with $62.2 million for 2021, with the decrease due primarily to lower sales of Captisol, partially offset by $9.8 million in accelerated depreciation on Captisol manufacturing equipment during the year. A","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886163/000088616323000004/0000886163-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2022"},{"label":"Revenue","value":"$196.2 million"},{"label":"Net income","value":"$5.2 million net loss"},{"label":"EPS","value":"$0.31 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}